-
HDAC Inhibitors Repress NUT Function in NUT Carcinoma
2026-08-17
This study developed a dCAS9-based transcriptional screen to identify compounds that suppress the oncogenic activity of BRD4-NUT in NUT carcinoma. It revealed that structurally distinct HDAC inhibitors can repress megadomain-driven transcription, induce tumor-cell differentiation, and enhance the activity of bromodomain inhibition in xenograft models.
-
A-769662 for Reliable AMPK Assays
2026-08-17
A practical, scenario-based guide to using A-769662 (SKU A3963) in cell viability, proliferation, cytotoxicity, and energy-metabolism workflows. It connects dose selection, DMSO handling, proteasome-related confounding, autophagy interpretation, and evidence-based product selection.
-
PD 173074: A Causal Assay Strategy for PAAD
2026-08-16
PD 173074 is more than a selective FGFR1 probe: it can help test whether computationally prioritized signaling dependencies in pancreatic adenocarcinoma are pharmacologically actionable. This article presents a causal assay framework that separates FGFR biology, VEGFR2 effects, and pyroptosis-related hypotheses.
-
Epidermal Growth Factor: Reliable Cell Assays
2026-08-15
A scenario-driven guide to using Epidermal Growth Factor (EGF), human recombinant (SKU P1008) to standardize proliferation, viability, cytotoxicity, and 3D spheroid workflows. It connects product specifications with dose interpretation, storage, assay controls, and literature-backed experimental design.
-
PYR-41: E1 Inhibitor Mechanism and Applications
2026-08-14
PYR-41 is an inhibitor of Ubiquitin-Activating Enzyme E1 that suppresses ubiquitin transfer at the first step of the ubiquitination cascade. Product data report cellular E1-thioester inhibition, NF-κB pathway effects, and activity in a mouse sepsis inflammation model, while the cited IBDV study provides proteasome-linked antiviral context rather than direct PYR-41 validation.
-
Recombinant Human EGF: Reliable Cell Assays
2026-08-14
A scenario-driven guide to using Epidermal Growth Factor (EGF), human recombinant in proliferation, viability, cytotoxicity, and 3D spheroid workflows. It explains how SKU P1008 supports controlled dosing, assay comparability, and practical reagent selection using product specifications and published protocol evidence.
-
Senescent CAFs Drive Breast Cancer Progression
2026-08-13
Ye and colleagues identify a senescent myofibroblast CAF population that suppresses natural killer cell activity through extracellular matrix remodeling, thereby promoting breast tumor growth. The findings connect stromal senescence with immune escape and support senCAF-directed interventions as a potential form of stromal therapy, while also linking senCAF abundance with recurrence risk in human breast lesions.
-
Batimastat (BB-94): From MMPs to Synapses
2026-08-13
Batimastat (BB-94) is more than a broad-spectrum MMP inhibitor: it is a translational tool for testing how extracellular proteolysis reshapes tissue behavior. This thought-leadership article connects its cancer-research utility with new mechanistic insights into localized BDNF processing during neuromuscular junction development.
-
Indole-3-pyruvic Acid Regulates Auxin Biosynthesis
2026-08-12
The 2022 PNAS study identifies indole-3-pyruvic acid (IPA, termed IPyA in the paper) as a feedback regulator of the tryptophan aminotransferase TAA1. Its kinetic, genetic, and comparative evidence explains how the two-step pathway for indole-3-acetic acid biosynthesis avoids excessive intermediate accumulation and operates across Arabidopsis, rice, and tomato.
-
LY2109761: Translating TGF-β Pathway Control
2026-08-12
A mechanistic and translational framework for using LY2109761, a TGF-β receptor type I and II dual inhibitor, to connect Smad2/3 pathway biology with oncology, radiosensitization, and fibrosis research.
-
Macrocyclic Hedgehog Inhibitors: Activity and Mechanism
2026-08-11
Dockendorff and colleagues used a modular build/couple/pair synthesis strategy to optimize macrocyclic Hedgehog pathway inhibitors and identify analogues with stronger cellular activity than robotnikinin. Their Ptch knockout and agonist-competition experiments further showed that selected compounds, including BRD-6851, behave as Smoothened antagonists rather than merely disrupting Sonic Hedgehog ligand interactions.
-
Standardized Whole-Blood Stimulation for Immunometabolism
2026-08-11
Zhao and colleagues present a standardized fresh whole-blood stimulation protocol for testing how metabolic interventions reshape cytokine responses to pattern-recognition and microbial stimuli. The workflow links donor-scale immune phenotyping with pathway perturbation, creating a practical framework for studying immunometabolism and comparing responses across cohorts.
-
CGF Reprograms CRC Metabolism to Drive Tumor Suppression
2026-08-10
The 2026 iScience study identifies Cya-Gly-Fer (CGF), a natural anthocyanin derivative from purple sweet potato, as an inhibitor of colorectal cancer growth and metastasis. Its central contribution is a mechanistic link between ABC transporter disruption, ATP accumulation, mitochondrial ROS overload, suppression of MAPK/ERK1/2/c-MYC signaling, cell-cycle arrest, and apoptosis.
-
Annexin V: Smarter Apoptosis Assay Design
2026-08-09
Annexin V is a calcium-dependent phosphatidylserine binding protein that converts an early membrane event into a measurable apoptosis assay signal. This guide focuses on assay architecture, controls, reagent format, and interpretation rather than repeating standard apoptosis detection workflows.
-
Calpain Inhibitor I, ALLN: Practical Guide
2026-08-08
Calpain Inhibitor I, ALLN (SKU A2602) provides research control of calpain I/II and cathepsin B/L activity in apoptosis, inflammation, and ischemia-reperfusion workflows. It is intended for non-clinical experiments only and requires DMSO-based preparation, vehicle controls, and empirical assay optimization because no universal cellular or in vivo dose is specified.